Recruiting studies: Diffuse Large B Cell Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3 · 175 location(s) · Janssen Research & Development, LLC · NCT01804686 Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07078500 Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07494565 Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumo
Phase 1/Phase 2 · 71 location(s) · Merck Sharp & Dohme LLC · NCT06395103 Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
EARLY_Phase 1 · 1 location(s) · He Huang · NCT06120166 Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell L
Phase 2 · 23 location(s) · Xynomic Pharmaceuticals, Inc. · NCT03936153 Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lym
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06774326 Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B C
Phase 1/Phase 2 · 1 location(s) · OHSU Knight Cancer Institute · NCT06249191 Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed
Phase 2 · 6 location(s) · Academic and Community Cancer Research United · NCT06238648 The CARDIOPROTECT Trial
Phase 2 · 1 location(s) · Beth Israel Deaconess Medical Center · NCT07654426 Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Phase 1 · 55 location(s) · National Cancer Institute (NCI) · NCT04609046 This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Phase 1 · 6 location(s) · LTZ Therapeutics, Inc. · NCT07121946 This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497 An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase 1 · 1 location(s) · Fudan University · NCT06517004 Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
Phase 2 · 2 location(s) · Sun Yat-sen University · NCT06742502 The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lympho
Phase 3 · 1 location(s) · Ruijin Hospital · NCT06522555 Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Phase 2 · 51 location(s) · Miltenyi Biomedicine GmbH · NCT04844866 The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728 Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
Phase N/A · 1 location(s) · Ain Shams University · NCT07057765 CR-CHOP+X in Previously Untreated DEL
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06701357 Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, a
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07608978 Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06043011 Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Phase 1/Phase 2 · 5 location(s) · Pell Bio-Med Technology Co., Ltd. · NCT05326243 A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refracto
Phase 2/Phase 3 · 135 location(s) · Merck Sharp & Dohme LLC · NCT05139017 CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · 7 location(s) · British Columbia Cancer Agency · NCT06208735 Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06589089 Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Phase 1 · 7 location(s) · AIDS Malignancy Consortium · NCT05077527 Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT05672251 Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)
Phase N/A · 4 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT04300101 A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma
Phase 2 · 2 location(s) · Shandong Cancer Hospital and Institute · NCT05933967

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.